（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：贵司盐酸毛果芸香碱滴眼液获批，请问预计2026年销 售渠道主要有哪些？该产品获批上市预计对提升业绩是否有较大帮助？ 欧普康视（300595.SZ）12月23日在投资者互动平台表示，盐酸毛果芸香碱滴眼液刚获得临床试验批 准，谈上市还早。药品的进展会按照规则披露。 ...

（文章来源：证券日报） 证券日报网讯 12月5日晚间，欧普康视发布公告称，欧普康视科技股份有限公司（以下简称"公司"）于 近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，批准公司的"盐酸毛果芸香碱滴眼 液"开展临床试验。 ...

Group 1: Major Transactions - Bohai Chemical is planning to sell 100% equity of Tianjin Bohai Petrochemical and acquire control of Anhui Taida New Materials through a combination of share issuance and cash payment, leading to a significant asset restructuring [1] - Zhongneng Electric is set to acquire 65% equity and debt from three companies, which may constitute a major asset restructuring but will not involve share issuance or change in control [4] - Hai Tai Development has decided to terminate the acquisition of controlling interest in Zhixueyun Technology due to disagreements on key terms, ensuring no adverse impact on normal business operations [5] Group 2: Performance Updates - Wen's shares reported a sales revenue of 3.324 billion yuan from meat chickens in November, marking a year-on-year increase of 10.18% [6] - Shuguang shares saw a 71.07% year-on-year increase in vehicle sales, totaling 207 units in November [6] - Muyuan shares experienced a decline in sales revenue from commodity pigs, reporting 9.39 billion yuan, a decrease of 20.43% year-on-year [6] - Pengding Holdings reported a 5.58% year-on-year decrease in consolidated revenue for November [6] Group 3: Industry Developments - Xiangxi Dairy reported a 6.3% month-on-month increase in fresh milk production in November, although it saw a year-on-year decline of 6.47% [7] - Baisheng Intelligent plans to acquire 51% equity in Zhongke Shengu, which focuses on the research and application of core technologies for embodied intelligent robots [7]

公告显示，盐酸毛果芸香碱是M-胆碱受体激动剂，可激活平滑肌（例如虹膜括约肌和睫状肌）的毒蕈 碱受体，通过虹膜括约肌的收缩，使瞳孔收缩，以增加焦深，改善近中视力，同时保持瞳孔对光的反 应，另外其还可收缩睫状肌，增强适应力，从而达到治疗成人老花眼的效果。 北京商报讯（记者 丁宁）12月5日晚间，欧普康视（300595）发布公告称，公司于近日收到国家药品监 督管理局下发的《药物临床试验批准通知书》，批准公司的"盐酸毛果芸香碱滴眼液"开展临床试验。 ...

Group 1 - Shareholder of Xidiwei plans to reduce holdings by up to 3% of total shares, amounting to 12.37 million shares [2] - Minsheng Bank successfully issued 6 billion yuan of 3-year floating rate financial bonds to optimize its liability structure [3] - Baisheng Intelligent intends to acquire 51% stake in Zhongke Shengu for 100 million yuan, with a preliminary valuation of up to 200 million yuan [4] Group 2 - Junshi Biosciences received acceptance for the new drug application of Rocaqi monoclonal antibody injection for treating moderate to severe plaque psoriasis [5] - Ganneng Co. announced the successful commissioning of its clean coal power project, achieving national performance standards [6] - Yuekang Pharmaceutical plans to issue H-shares and list on the Hong Kong Stock Exchange [7][8] Group 3 - Qingtang City received notice of expropriation for Huaneng Mall, which will be shut down pending approval processes [9] - Meilixin's controlling shareholder plans to increase holdings by 50 million to 100 million yuan, with a maximum price of 52 yuan per share [10] - Zhenghong Technology reported a 20.43% year-on-year decline in November pig sales revenue [11][12] Group 4 - GAC Group reported a 9.72% year-on-year decline in November automobile sales, totaling 179,700 units [16] - Oupokangshi received approval for clinical trials of a new eye drop for treating presbyopia [17] - Kang En Bei announced the resignation of its chairman and legal representative due to work adjustments [18] Group 5 - Jiangxi Changyun is set to receive 15.7 million yuan in compensation for the expropriation of part of its properties [28] - Tianrun Dairy reported a 2.99% month-on-month increase in November pig sales revenue [29] - New Point Software won a 54 million yuan contract for a digital smart community construction project [31]

Company Overview - Opcon Vision (SZ 300595) announced on December 5 that it received the "Drug Clinical Trial Approval Notification" from the National Medical Products Administration for its "Pilocarpine Hydrochloride Eye Drops" to conduct clinical trials [1] - As of the report date, Opcon Vision has a market capitalization of 14 billion yuan [1] Revenue Composition - For the year 2024, the revenue composition of Opcon Vision is as follows: - Rigid contact lens industry accounts for 56.18% - Medical industry accounts for 20.04% - Other optometry and professional services account for 19.47% - Non-optometry and others account for 4.31% [1]

据悉，盐酸毛果芸香碱是M-胆碱受体激动剂，可激活平滑肌(例如虹膜括约肌和睫状肌)的毒蕈碱受体， 通过虹膜括约肌的收缩，使瞳孔收缩，以增加焦深，改善近中视力，同时保持瞳孔对光的反应，另外其 还可收缩睫状肌，增强适应力，从而达到治疗成人老花眼的效果。 智通财经APP讯，欧普康视(300595.SZ)发布公告，公司于近日收到国家药品监督管理局下发的《药物临 床试验批准通知书》(通知书编号：2025LP03261)，批准公司的"盐酸毛果芸香碱滴眼液"开展临床试 验。 ...

Core Viewpoint - The company, Opcon Vision (300595.SZ), has received approval from the National Medical Products Administration for clinical trials of its drug, "Pilocarpine Hydrochloride Eye Drops" [1] Group 1: Company Developments - The approval notification number for the clinical trial is 2025LP03261 [1] - The drug, Pilocarpine Hydrochloride, is an M-cholinergic receptor agonist that activates smooth muscle, specifically the iris sphincter and ciliary muscle [1] - The drug aims to treat presbyopia in adults by inducing pupil constriction to increase depth of focus and improve near and intermediate vision while maintaining light response [1] Group 2: Industry Context - The mechanism of action involves the contraction of the iris sphincter to enhance depth of focus and the contraction of the ciliary muscle to improve adaptability [1]

人民财讯12月5日电，欧普康视（300595）12月5日公告，公司近日收到国家药监局下发的《药物临床试 验批准通知书》，批准公司的"盐酸毛果芸香碱滴眼液"开展临床试验，申请的适应症为治疗成人老花 眼。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its "Pilocarpine Hydrochloride Eye Drops" [1] Group 1 - The approval notification number is 2025LP03261 [1]